{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:11:50Z","timestamp":1791277910936,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T00:00:00Z","timestamp":1287446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression\u2010free survival, and event\u2010free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR\u2010ABL1 transcript levels and caveats of molecular monitoring are also described. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.25527","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T11:15:13Z","timestamp":1287486913000},"page":"1113-1122","source":"Crossref","is-referenced-by-count":41,"title":["Monitoring molecular response in chronic myeloid leukemia"],"prefix":"10.1002","volume":"117","author":[{"given":"Jorge","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quint\u00e1s\u2010Cardama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144790"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1567"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.005"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403241"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_6_7_2","first-page":"464","article-title":"Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: clinical response, safety, and long\u2010term outcomes","volume":"114","author":"Kantarjian HM","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11223"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23238"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01749.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1929.1929"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404139"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"16a","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long\u2010term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot F","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403033"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2574"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1112"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V112.11.334.334","article-title":"Reduction of BCR\u2010ABL transcript levels at 6, 12, and 18 months (mo) correlates with long\u2010term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML\u2010CP)","volume":"112","author":"Hughes TP","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4406"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403158"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V112.11.333.333","article-title":"Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia: an interim analysis of the randomized German CML study IV","volume":"112","author":"Muller MC","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04200.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166694"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6999"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.LBA-1.LBA-1"},{"key":"e_1_2_6_36_2","first-page":"144","article-title":"Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (ph)\u2010positive chronic myelogenous leukemia in early chronic phase (CML\u2010CP)","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_37_2","first-page":"143","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML\u2010CP)","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902926973"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1335"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients","volume":"114","author":"Mahon FX","year":"2009","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25527","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:25:45Z","timestamp":1760300745000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,19]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,3,15]]}},"alternative-id":["10.1002\/cncr.25527"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25527","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,19]]}}}